RT Journal Article
SR Electronic
T1 LncRNA antigens- a novel resource to improve immunotherapy efficacy predictions in Melanoma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.30.23290735
DO 10.1101/2023.05.30.23290735
A1 Sumaira Malik
A1 Aaron Golden
YR 2023
UL http://medrxiv.org/content/early/2023/06/01/2023.05.30.23290735.abstract
AB Background ICI (immune checkpoint inhibitor) therapy is one of the most promising treatments for melanoma. ICI response however varies among patients, emphasizing the importance of identifying genomic biomarkers to predict likely therapeutic efficacy in advance of treatment. We hypothesised that a lncRNA based immunogencity (lnc-IM) score could be used to predict individual response to ICI treatment, and that this could complement the existing criterion for ICI selection based on tumor mutation burden (TMB).Methodology The TCGA-SKCM (n=101) and the ICI treated UCLA (n=25), MSKCC (n=16) and DFCI (n=40) melanoma cohorts were used in this study, involving both clinical and transcriptomic data. Each patient was assigned an lnc-IM score based on the number of lncRNA sORF derived peptides predicted to be presented by their tumor’s MHC-I genotype. For the ICI treated cohorts, a combined antigen score was defined as a sum of neo-antigen load (derived from TMB) and lnc-IM score. A logistic regression-based classifier was used to predict ICI responses based on these combined antigen scores.Results Survival analysis showed improved overall survival among patients with low lnc-IM scores (HR= 0.39, p=0.009) in the TCGA-SKCM cohort. We also observed a negative association between tumor immune cell concentration and lnc-IM scores, with low lnc-IM groups showing higher anti-tumor immune cell concentrations . Using the ICI treated cohorts, we demonstrated that a classifier based on combined antigen scoring improved the prediction of immunotherapy outcomes as compared to using TMB alone, yielding an area under the curve (AUC) of 0.71 with an accuracy of 0.54 and recall of 1. We also demonstrated a reduced rate of false negatives (14%) by using a combined antigen score as compared to the use of TMB alone (33%) in ICI treated cohorts.Conclusion Our findings suggest that the use of combined antigen scores (using lnc-IM scores along with TMB derived neoantigen load) have potential in improving immunotherapy efficacy predictions. Prospective validation in larger cohort sizes is warranted.What is already known on this topic Previous studies have established actionable associations between TMB neoantigen load and immunotherapy responses.What this study adds This study introduces lnc-IM scores as a novel metric that predicts patients antigen load based on translatable lncRNAs expression. These lnc-IM scores when combined with TMB associated neoantigen load indicate an improvement in immunotherapy efficacy predictions.How this study might affect research, practice or policy Future research is needed to further validate lnc-IM scores as a predictive biomarker for immunotherapy response in various cancer types. The use of lnc-IM scores can empower clinicians to make more informed decisions about administering immunotherapy treatments, improvingpatient outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by a Hardiman Research Scholarship, University of Galway, IrelandAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:TCGA (https://portal. gdc.cancer.gov) cBioPortal (https://www.cbioportal.org/)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://portal.gdc.cancer.gov https://www.cbioportal.org/ ICIImmune checkpoint inhibitor therapylnc-IM scoreLncRNA based immunogencity scoreTMBTumor mutation burdenAUCArea under the curvePDL1Programmed cell death ligand 1dMMRMismatch repair defectMSIMicrosatellites InstabilityENCODEEncyclopedia of DNA ElementsCTLCytotoxic T lymphocytesORFsShort open reading framesTIMTumor immune microenvironmentTCGAThe Cancer Genome AtlascpmCounts per millionPHBRPatient Harmonic mean Best RanTILsTumor infiltrating lymphocytesORROverall response ratesHRHazard ratio